Aidnega Hong Kong Limited



MammaPrint Provides Individualized Metastasis Risk Assessment for Breast Cancer Patients. MammaPrint is the first and only FDA-cleared IVDMIA breast cancer recurrence assay. The unique 70-gene signature of MammaPrint provides you with the unprecedented ability to identify which early-stage breast cancer patients are at risk of distant recurrence following surgery, independent of Estrogen Receptor status and any prior treatment.


A Molecular Subtyping Profile for Breast Cancer. Agendia developed BluePrint, a multi-gene profile, for the classification of breast cancer into Basal-type, Luminal-type and ERBB2-type (HER2/neu positive) molecular subclasses. Following risk assessment with a MammaPrint 'low risk' or 'high risk' result, additional stratification into a molecular subtype provides the next level of genomic breast cancer analysis.


Provides Quantification of ER, PR and HER2 Status. TargetPrint is offered in conjunction with MammaPrint to provide the physician an even more complete basis for treatment decisions.


Delivering Clinically Relevant Gene Therapy Analysis for Cancer Patients. Knowledge of a tumor's gene expression can be used to predict the ability of an individual's cancer to spread and may predict its response to chemotherapy and targeted biologic therapies. As the scientific and medical community gains a deeper understanding into the role these genes play in disease progression and treatment, this information may offer patients access to novel therapies and a greater level of personalized treatment.

Useful Link
Contact Us
Main Menu








HomeProfileProductsCalendarUseful LinksContact UsMain Menu

Copyright © 2011 Aidnega Hong Kong Limited. All Rights Reserved.